Stinchcombe TE, et al. - Researchers compared overall survival (OS), progression-free survival (PFS), the rate of severe adverse events (AEs), and off-treatment reasons among 1,049 younger patients (81%) and 254 elderly patients (19%) with limited-stage small cell lung cancer (LS-SCLC) receiving concurrent chemoradiotherapy. They analyzed individual patient data from 11 phase 2 or 3 trials for LS-SCLC conducted by the National Clinical Trials Network. According to findings, worse PFS and OS were observed among elderly patients with LS-SCLC. Furthermore, more grade 5 AEs and more grade 3 or higher dyspnea but less grade 3 or higher esophagitis/dysphagia and less grade 3 or higher vomiting were experienced by elderly vs younger patients. More frequent treatment discontinuation due to AEs and more frequent patient refusal was observed in elderly patients. These participants completed treatment less often and, overall, experienced more difficulty in tolerating therapy.